A multicentre phase-II trial of thalidomide in relapsed/refractory multiple myeloma (MM) reveals a dominant adverse prognostic impact of advanced age.

被引：0
|
作者：
Prince, M
Mileshkin, L
Biagi, JJ
Smith, JG
Mitchell, P
Underhill, C
Grigg, A
Bell, R
McKendrick, J
Briggs, P
Seymour, JF
Simmons, PJ
Zeldis, JB
机构：
[1] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
[2] Austin Repatriat Med Ctr, Heidelberg, Vic, Australia
[3] Border Med Oncol, Wodonga, Australia
[4] Royal Melbourne Hosp, Melbourne, Vic, Australia
[5] Geelong Hosp, Geelong, Vic, Australia
[6] Box Hill Hosp, Box Hill, Australia
[7] Monash Med Ctr, Clayton, Vic 3168, Australia
[8] Celgene Corp, Wayne, NJ 07059 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1559
引用
收藏
页码：401A / 402A
页数：2
相关论文
共 50 条
  • [21] Interim analysis of a phase II trial of nab-paclitaxel in patients with very advanced relapsed/refractory multiple myeloma (RR-MM).
    Rosenthal, Allison Claire
    Fonseca, Rafael
    Mikhael, Joseph
    Stewart, A. Keith
    Mayo, Angela
    Chesi, Marta
    Kosiorek, Heidi
    Bergsagel, P. Leif
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Combination of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial
    Palumbo, Antonio
    Falco, Patrizia
    Sanpaolo, Grazia
    Falcone, Antonietta
    Ferderico, Vincenzo
    Canepa, Letizia
    Crugnola, Monica
    Baldini, Luca
    Larocca, Alessandra
    Magarotto, Valeria
    Petrucci, Maria Teresa
    Boccadoro, Mario
    BLOOD, 2008, 112 (11) : 321 - 321
  • [23] ETOPOSIDE PLUS IDARUBICIN AND PREDNISONE IN REFRACTORY OR RELAPSED MULTIPLE-MYELOMA - A PHASE-II STUDY
    CAPNIST, G
    CHISESI, T
    HAEMATOLOGICA, 1988, 73 (05) : 431 - 432
  • [24] A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial
    Bergin, Krystal
    Yuen, Flora
    Wallington-Beddoe, Craig
    Kalff, Anna
    Sirdesai, Shreerang
    Reynolds, John
    Spencer, Andrew
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (03) : 580 - 586
  • [25] Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study
    Hovenga, S
    Daenen, SMGJ
    de Wolf, JTM
    van Imhoff, GW
    Kluin-Nelemans, HC
    Sluiter, WJ
    Vellenga, E
    ANNALS OF HEMATOLOGY, 2005, 84 (05) : 311 - 316
  • [26] Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM)
    Shah, J. J.
    Cohen, A. D.
    Zonder, J. A.
    Kaufman, J. L.
    Burt, S. M.
    Freeman, B. B.
    Rush, S.
    Ptaszynski, A. M.
    Orlowski, R. Z.
    Lonial, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] A phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for patients with relapsed/refractory multiple myeloma (MM).
    Berenson, James R.
    To, Jennifer
    Spektor, Tanya M.
    Martinez, Daisy
    Sanchez, Armando Jose
    Ghermezi, Matthew
    Turner, Carley
    Swift, Regina A.
    Eades, Benjamin M.
    Schwartz, Gary
    Eshaghian, Shahrooz
    Stampleman, Laura
    Moss, Robert A.
    Nassir, Youram
    Patel, Ravindranath
    Bessudo, Alberto
    Lim, Stephen
    Vescio, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)
    Berenson, James R.
    To, Jennifer
    Spektor, Tanya M.
    Martinez, Daisy
    Sanchez, Armando J.
    Turner, Carley
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Stampleman, Laura V.
    Moss, Robert A.
    Nassir, Youram
    Patel, Ravindranath
    Bessudo, Alberto
    Greenwald, Daniel
    Boccia, Ralph V.
    Lim, Stephen
    Vescio, Robert
    BLOOD, 2019, 134
  • [29] Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study
    Sjoerd Hovenga
    Simon M. G. J. Daenen
    Joost T. M. de Wolf
    Gustaaf W. van Imhoff
    Hanneke C. Kluin-Nelemans
    Wim J. Sluiter
    Edo Vellenga
    Annals of Hematology, 2005, 84 : 311 - 316
  • [30] Bendamustine in combination with thalidomide and prednisolone (BPT) in patients with refractory or relapsed multiple myeloma (MM): Preliminary results of a phase I clinical trial.
    Poenisch, W
    Rozanski, M
    Leiblein, S
    Goldschmidt, H
    Wegner, A
    Niederwieser, D
    BLOOD, 2004, 104 (11) : 307B - 307B
12345